{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T05:25:12Z","timestamp":1791523512406,"version":"4.3.4"},"reference-count":22,"publisher":"Wiley","issue":"11","license":[{"start":{"date-parts":[[2019,10,22]],"date-time":"2019-10-22T00:00:00Z","timestamp":1571702400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["accpjournals.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Pharmacotherapy"],"published-print":{"date-parts":[[2019,11]]},"abstract":"<jats:p>\n                    Multidrug\u2010resistant (MDR)\n                    <jats:italic>Pseudomonas aeruginosa<\/jats:italic>\n                    infections often represent a therapeutic challenge requiring utilization of older, more toxic antibiotics, or new agents with limited data. Once susceptibility to \u03b2\u2010lactam and fluoroquinolone antibiotics has been lost, other therapeutic options such as aminoglycoside or polymyxin antibiotics carry significant adverse effects such as nephrotoxicity, neurotoxicity, and ototoxicity. A novel cephalosporin, cefiderocol, lacks gram\u2010positive and anaerobic activity but offers broad coverage of gram\u2010negative bacteria, including\n                    <jats:italic>P.\u00a0aeruginosa<\/jats:italic>\n                    . A unique catechol side chain gives it activity as a siderophore, thereby increasing bacterial uptake and decreasing efflux. Additionally, cefiderocol is stable against a wide array of \u03b2\u2010lactamases. Despite these promising characteristics, there are minimal data currently available in the literature detailing the use of cefiderocol in the treatment of MDR\n                    <jats:italic>P.\u00a0aeruginosa<\/jats:italic>\n                    infections. We present a case of a 46\u2010year\u2010old man who developed an MDR\n                    <jats:italic>P.\u00a0aeruginosa<\/jats:italic>\n                    intraabdominal infection where serious and life\u2010threatening toxicities to aminoglycosides and polymyxin antibiotics led to the utilization of cefiderocol on compassionate use approval. The isolate was susceptible to cefiderocol, and the patient was treated for 28\u00a0days of therapy. He demonstrated clinical and radiographic resolution of his infection and was discharged to home.\n                  <\/jats:p>","DOI":"10.1002\/phar.2334","type":"journal-article","created":{"date-parts":[[2019,9,24]],"date-time":"2019-09-24T11:16:13Z","timestamp":1569323773000},"page":"1113-1118","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":37,"title":["Compassionate Use of Cefiderocol in the Treatment of an Intraabdominal Infection Due to Multidrug\u2010Resistant\n                    <i>Pseudomonas aeruginosa<\/i>\n                    : A Case Report"],"prefix":"10.1002","volume":"39","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5050-6689","authenticated-orcid":false,"given":"Ryan W.","family":"Stevens","sequence":"first","affiliation":[{"name":"Mayo Clinic Saint Mary\u2019s Medical Center Rochester Minnesota"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Megan","family":"Clancy","sequence":"additional","affiliation":[{"name":"Providence Alaska Medical Center Anchorage Alaska"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2019,10,22]]},"reference":[{"key":"e_1_2_6_2_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-019-1055-2"},{"key":"e_1_2_6_3_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01454-17"},{"issue":"12","key":"e_1_2_6_4_1","doi-asserted-by":"crossref","first-page":"7396","DOI":"10.1128\/AAC.01405-16","article-title":"Siderophore cephalosporin cefiderocol utilizes ferric iron transporter systems for antibacterial activity against Pseudomonas aeruginosa","volume":"60","author":"Ito A","year":"2016","journal-title":"Antimicrob Agents Chemother"},{"issue":"41","key":"e_1_2_6_5_1","first-page":"22","article-title":"Mechanisms of antibiotic resistance in Pseudomonas aeruginosa","volume":"95","author":"Lambert PA","year":"2002","journal-title":"J R Soc Med"},{"key":"e_1_2_6_6_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02163-17"},{"key":"e_1_2_6_7_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01391-17"},{"key":"e_1_2_6_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(18)30554-1"},{"key":"e_1_2_6_9_1","unstructured":"Shionogi Press Release.Shionogi announces submission of cefiderocol marketing authorization application. Available fromhttp:\/\/www.shionogi.co.jp\/en\/company\/news\/2019\/pmrltj000000418y-att\/e_190401_2.pdf. Published April 1 2019. Accessed June 13 2019."},{"key":"e_1_2_6_10_1","unstructured":"Clinical Laboratory Standards Institute.Subcommittee (SC) on antimicrobial susceptibility testing. (2018 June 3\u20135). Available fromhttps:\/\/clsi.org\/media\/3013\/2018_june_ast_agenda_summary_minutes_approved.pdf. Published June 2018. Accessed June 14 2019."},{"key":"e_1_2_6_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(16)30004-4"},{"key":"e_1_2_6_12_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.03074-15"},{"key":"e_1_2_6_13_1","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofz273"},{"key":"e_1_2_6_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2018.03.013"},{"key":"e_1_2_6_15_1","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkz318"},{"key":"e_1_2_6_16_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciy963"},{"key":"e_1_2_6_17_1","doi-asserted-by":"publisher","DOI":"10.1002\/phar.2209"},{"key":"e_1_2_6_18_1","doi-asserted-by":"publisher","DOI":"10.1177\/2324709616638362"},{"key":"e_1_2_6_19_1","doi-asserted-by":"publisher","DOI":"10.1007\/s15010-014-0704-3"},{"key":"e_1_2_6_20_1","doi-asserted-by":"publisher","DOI":"10.1378\/chest.11-1483"},{"key":"e_1_2_6_21_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01617-17"},{"key":"e_1_2_6_22_1","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.1981.154"},{"key":"e_1_2_6_23_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01381-16"}],"container-title":["Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/phar.2334","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/phar.2334","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/accpjournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/phar.2334","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T17:39:51Z","timestamp":1761068391000},"score":1,"resource":{"primary":{"URL":"https:\/\/accpjournals.onlinelibrary.wiley.com\/doi\/10.1002\/phar.2334"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,10,22]]},"references-count":22,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2019,11]]}},"alternative-id":["10.1002\/phar.2334"],"URL":"https:\/\/doi.org\/10.1002\/phar.2334","archive":["Portico"],"relation":{},"ISSN":["0277-0008","1875-9114"],"issn-type":[{"value":"0277-0008","type":"print"},{"value":"1875-9114","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,10,22]]},"assertion":[{"value":"2019-10-22","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}